A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.

An injectable peptide-based hydrogel is disclosed that incorporates a peptide inhibitor of proprotein convertase subtilisn/kexin type 9. The hydrogel is a polymer composed of the 13-amino-acid protein, Pep2-8, (TVFTSWEEYLDWV) attached to a self-assembling peptide of the ABA block structure (ESLSLSLSLSLSLEG) to generate the repeating multidomain peptide sequence (ESLSLSLSLSLSLEGTVFTSWEEYLDWV).

The purpose of the present invention is to provide a modified activin A.

The present invention provides activin A comprising a modified proregion.

The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.

Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.

Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells). The pre-fusion state SARS-CoV-2 spike protein can be used as an antigen to generate antibodies/binding molecules for use in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; as a therapeutic to interfere with SARS-CoV-2 cellular binding; to generate antibodies/binding molecules to SARS-CoV-2 for use in therapy; or, as a vaccine for generating immunity to SARS-CoV-2; or for prophylactic or therapeutic use against related coronaviruses.

The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo.

Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.

The present invention relates to novel short chain peptides of formula (I) which can be useful as a vaccine when in conjugation with suitable immunogenic carrier and suitable adjuvant. These are useful for the treatment for the PCSK9 mediated diseases.

A-Z.sub.1Z.sub.2Z.sub.3Z.sub.4Z.sub.5Z.sub.6Z.sub.7Z.sub.8Z.sub.9Z.sub.10Z.sub.11Z.sub.12B Formula (I)

The present disclosure provides improved genome editing compositions and methods for editing a PCSK9 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of hypercholesterolemia or a condition associated therewith.